临床前CDMO研发筛选相关化合物

CDMO是Contract Development and Manufacturing Organization的缩写，即合同定制研发生产组织。它是一种为制药企业及生物技术公司提供医药（特别是创新药）工艺研发及制备、工艺优化、放大生产、注册和验证批生产以及商业化生产等定制服务的机构. 在传统代工基础上增加了研发和工艺优化能力，是高技术壁垒的工艺研发能力与规模生产能力的深度结合. 1, 工艺开发与优化：创新性合成路线设计、工艺参数优化. 2, 中试放大：实验室工艺向规模化生产的转化 3, 注册批生产：支持客户新药申报的验证批生产. 4, 商业化生产：药品上市后的大规模生产供应. 全球医药CDMO行业保持较高景气度。根据弗若斯特沙利文预测：2026年全球CDMO市场规模：预计达1,189亿美元 2033年全球CDMO市场规模：预计达3,385亿美元. CDMO作为医药产业链专业化分工的产物，已经从单纯的CMO代工模式升级为"研发+生产"一体化的高附加值服务。当前，在多肽、ADC、CGT等新型药物赛道的驱动下，全球及中国CDMO市场保持高速增长。中国CDMO企业凭借完整的供应链体系、工程师红利和一体化服务能力，全球市占率有望持续提升，行业正从"成本优势"竞争迈向"体系优势"竞争的新阶段。
如有产品调研服务, 请致函联系我们

客户展示

临床前CDMO研发化合物筛选

CAS: 1374248-77-7

Ubrogepant

中文名称:乌布吉泮
CAS号:1374248-77-7
分子式: C29H26F3N5O3 分子量: 549.54
产品形式: free base
研发状态: Completed
研发用途: Healthy Volunteers
研究机构: AbbVie
研发日期: July 11 2023
研发阶段: Phase 1
Ubrogepant (MK-1602) is an antagonist of human calcitonin gene-related peptide receptor (CGRP). It potently blocks human α–CGRP–stimulated cAMP responses with an IC50 of 0.081 nM in human CGRP receptor-expressing HEK293 cells.

CAS: 13739-02-1

Diacerein

中文名称:双醋瑞因; 二乙酰大黄酸; 二乙酰二氢蒽羧酸
CAS号:13739-02-1
分子式: C19H12O8 分子量: 368.29
产品形式: free base
研发状态: Completed
研发用途: Epidermolysis Bullosa (EB); Epidermolysis Bullosa Simplex; Dystrophic Epidermolysis Bullosa; Junctional Epidermolysis Bullosa
研究机构: Castle Creek Pharmaceuticals LLC
研发日期: May 18 2018
研发阶段: Phase 1
Diacerein is an inhibitor of pro-inflammatory cytokine Interleukin-1B (IL-1B) production, prescribed for osteoarthritis and chronic inflammatory arthritis.

CAS: 1373215-15-6

LY3000328

中文名称:N-[(3R,4S)-3,4-二氢-3-[[(甲基氨基)羰基]氧基]-6-[4-(3-氧杂环丁基)-1-哌嗪基]-2H-1-苯并吡喃-4-基]-4-氟-苯甲酰胺
CAS号:1373215-15-6
分子式: C25H29FN4O5 分子量: 484.52
产品形式: free base
研发状态: Completed
研发用途: Healthy Volunteers
研究机构: Eli Lilly and Company
研发日期: Feb-12
研发阶段: Phase 1
LY 3000328 (Z-FL-COCHO, Compound 5) is a potent and selective Cathepsin S (Cat S) inhibitor with IC50s of 7.7 and 1.67 nM for human Cat S and mouse Cat S, respectively.

CAS: 137281-23-3

Pemetrexed

中文名称:培美曲塞二钠盐
CAS号:137281-23-3
分子式: C20H21N5O6 分子量: 427.41
产品形式: Free Base
研发状态: Recruiting
研发用途: Non Small Cell Lung Cancer Metastatic; ALK Gene Mutation
研究机构: Centro di Riferimento Oncologico - Aviano
研发日期: March 15 2024
研发阶段: Phase 2
Pemetrexed (LY231514, Alimta) is a novel antifolate and antimetabolite for thymidylate synthase (TS), dihydrofolate reductase (DHFR) and glycinamide ribonucleotide formyltransferase (GARFT) with Ki of 1.3 nM, 7.2 nM and 65 nM in cell-free assays, respectively. Pemetrexed induces autophagy and apoptosis.

CAS: 1372540-25-4

GSK2636771

中文名称:2-甲基-1-[[2-甲基-3-(三氟甲基)苯基]甲基]-6-(4-吗啉基)-1H-苯并咪唑-4-羧酸
CAS号:1372540-25-4
分子式: C22H22F3N3O3 分子量: 433.42
产品形式: free base
研发状态: Active not recruiting
研发用途: Melanoma and Other Malignant Neoplasms of Skin; Metastatic Melanoma
研究机构: M.D. Anderson Cancer Center; National Cancer Institute (NCI); National Institutes of Health (NIH); Merck Sharp & Dohme LLC; GlaxoSmithKline
研发日期: July 17 2017
研发阶段: Phase 1 : Phase 2
GSK2636771 is a potent, orally bioavailable and selective inhibitor of PI3Kβ with >900-fold selectivity over PI3Kα/PI3Kγ and >10-fold over PI3Kδ. Sensitive to PTEN null cell lines.

CAS: 137234-62-9

Voriconazole (UK-109496)

中文名称: 伏立康唑
CAS号:137234-62-9
分子式: C16H14F3N5O 分子量: 349.31
产品形式: free base
研发状态: Terminated
研发用途: Haematological Malignancies
研究机构: AstraZeneca
研发日期: June 11 2021
研发阶段: Phase 1 : Phase 2
Voriconazole (Vfend,UK-109496) is a new triazole derivative similar to fluconazole and itraconazole that acts by inhibiting fungal cytochrome P-450-dependent, 14-alpha-sterol demethylase-mediated synthesis of ergosterol.